针对前列腺素E_1治疗肝硬化的临床疗效及安全性评价

Clinical Efficacy and Safety Evaluation for Treatment of Cirrhosis of Prostaglandin E_1

目的探析肝硬化患者应用前列腺素E1治疗的临床效果及安全性。方法对我院2014年2月至2016年3月期间收治的86例肝硬化患者予以分组研究,即参照组与治疗组,各组43例。参照组患者给予常规药物治疗,治疗组患者加用前列腺素E1治疗,对两组患者的治疗效果进行观察比较。结果治疗组患者的临床总有效率是93.0%,与参照组患者的76.7%进行对比,组间差异明显(P<0.05)。治疗后,两组患者的白蛋白含量明显增多,血清总胆红素、丙氨酸氨基转移酶、门冬氨酸氨基转移酶含量明显降低,且治疗组患者增多与降低更加明显(P<0.05)。治疗组患者的不良反应发生率为2.3%,与参照组患者的14.0%进行对比,组间差异明显(P<0.05)。结论肝硬化患者应用前列腺素E1治疗的临床效果确切,能够明显改善患者的肝功能指标,具有安全、可靠的特点,是一种适合临床推广与应用的治疗方法。

Objective To explore the clinical effect of prostaglandin El treatment of patients with liver cirrhosis and security. Methods In our hospital in February 2014 to March 2016 admitted during the period of 86 patients with liver cirrhosis group study, namely the control group and treatment group, each group 43 cases. Results The total group of patients with clinical response rate was 93.0%, and 76.7% of patients were compared with reference group, significant differences between the groups （P〈0.05）. After treatment, the two groups of patients with albumin significantly increased serum total bilirubin, alanine aminotransferase, aspartate aminotransferase were significantly reduced, and the treatment of patients with decreased more significantly increased （P〈0.05）. Adverse reactions occurred in patients treated with 2.3%, and 14.0% of patients were compared with reference group, significant differences between the groups （P〈0.05）.,Conclusiou The clinical effect of prostaglandin E1 treatment of patients with liver cirrhosis, exactly can obviously improve the patient＇s liver function index, has the characteristics of safe, reliable, and is a kind of suitable for clinical treatment of popularization and application.